Angion Awarded $4.76 Million Department of Defense Grant for Chronic Kidney Disease Drug Candidate ANG-3070
April 2019

Angion Completes Equity Financing and Appoints Senior Executives
January 2019

Angion Biomedica to present at Piper Jaffray Healthcare Conference
November 2018

Angion Biomedica and Sinovant Sciences Enter into Collaboration and License Agreement to Develop BB3 in Greater China
November 2018

Angion Biomedica expands staff with new Director of Chemistry and Director of Clinical Operations
September 2017

Angion Biomedica Corp. in-licenses aldosterone synthase inhibitors from ElexoPharm GmbH, complementing its ongoing program in chronic kidney Disease 
June 2017

Angion Biomedica Corp.'s Phase 2 GUARD Clinical Trial of BB3 in Acute Kidney Injury (AKI) Underway; Complements Ongoing Phase 3 Study in Renal Recipients with Delayed Graft Function 
January 2017

Angion Biomedica to Present Clinical and Preclinical Data at the Upcoming American Society of Nephrology Conference in San Diego 
November 2015

Angion Biomedica Corp. To Commence Phase 2 Clinical Trial of BB3 in Acute Kidney Injury 
June 2015

Angion Biomedica Corp. Advances BB3 into Pivotal Phase 3 Clinical Trial in Renal Transplant Patients with Delayed Graft Function 
May 2015


Two abstracts to be included in the American Society for Nephrology 2017 Annual Meeting (Kidney Week, October 31-November 5, New Orleans LA)
September 2017

Four abstracts to be presented at the American Society for Nephrology 2015 Annual Meeting (Kidney Week, November 3-8, San Diego CA)
November 2015

Angion Biomedica with Duke University and Massachusetts General Hospital Researchers Publish on Efficacy of BB3 in Stroke in Rodent Models
March 2015